-
EntrepreneurKurve Therapeutics The Future of Systemic and Central Nervous System (CNS) Therapies - Bringing solutions to clinical unmet needs
-
EntrepreneurCreative BioTherapeutics WE START WHERE OTHER THERAPIES FAIL FOR RECURRENT & DRUG RESISTANT CANCERS
-
EntrepreneurGel Dynamics A Vetted Solution With A Global Market
-
EntrepreneurTitin KM Biomedical Corporation THE FUTURE OF SHOULDER REHABILITATION
-
EntrepreneurAdlore Introducing SenLore - A Novel Device to Treat and Monitor Diabetic Foot Ulcers
-
EntrepreneurVIC Tech A LIFE SCIENCE VENTURE STUDIO - Building a Healthy Future
-
EntrepreneurIMEX USA Bank Where You Shop® Send, Spend, Save. Simple®
-
EntrepreneurTorque3 Transformative Stroke Recovery
-
EntrepreneurFuzelo The Future of Telehealth and Telefitness Technology
-
EntrepreneurCommerceBlitz Optimizing Inventory and Distribution Operations for eCommerce Businesses
-
EntrepreneurSoon Crypto Investing Automated & Easy
-
EntrepreneurSeekingSimple Improved health through better processed food choices to address food related disease for 230M in the US and the resulting $1.1T problem for healthcare payors
-
EntrepreneurMedAware Transforming patient safety
-
Information
iCFO Information Booth How can we help? -
Entrepreneur
STRATAFOLIO Total Commercial Property Management Platform
-
Entrepreneur
Nob Hill Therapeutics Pioneering Respiratory Patient Care
-
Entrepreneur
PROOF Hard Ice Cream PROOF will be among the most highly recommended gourmet brands in the world
Event DealConnect 360: The Ultimate Deal Room for Real Results! is over.
Join us next time to meet Jeff Galvin!
Join us next time to meet Jeff Galvin!
About Addimmune
Addimmune
Addimmune’s sole purpose is to cure HIV. We believe it’s possible with gene and cell therapy.
Available from
12:00 PM
-
4:00 PM
(US/Pacific)
+1 301-337-2108
Addimmune is a Rockville, Maryland-based, clinical-stage cell and gene therapy company with a line of sight on a functional HIV cure. We have completed a successful FDA-approved Phase I human clinical trial with no serious adverse events and have shown blood markers of efficacy in all seven treated trial participants. An IRB-approved treatment interruption protocol demonstrated the reconstitution of the immune systems of the six who consented to participate. A $50M capital raise is being undertaken in conjunction with 10X Capital, our Wall Street partners with whom we plan a public transaction via de-SPAC in Q1 of next year, to fund our next phase human clinical trial also to begin in Q1 of 2024.
